OBJECTIVES: The objective of this study was to investigate the prevalence of different polymorphisms and haplotypes associated with individual variations in pharmacokinetics and drug toxicity in the uridine-diphosphate glucuronosyl transferase (UGT) 1A gene in a Swedish cohort (248 healthy volunteers) and in 14 different ethnic groups. We also estimated UGT1A genotype-dependent glucuronidation efficiency using the endogenous substrate bilirubin as an indicator. METHODS: Pyrosequencing-based genotyping assays were used to determine the different polymorphisms and haplotypes. RESULTS: Haplotype analysis of the UGT1A1 (*1*28), UGT1A6 (*1*2), and UGT1A7(*1*2*3*4) allelic variants showed that three major haplotypes constituted 84% of the allelic variants in the cohort. We identified 15 haplotypes altogether from all groups, including previously undescribed haplotypes. Testing for the association of genotype and total bilirubin levels (nonfasting) in plasma disclosed that homozygous carriers of the TA allele, irrespective of haplotype combinations, had increased levels of bilirubin compared with noncarriers, but a gender-associated difference was observed. CONCLUSIONS: In a Swedish cohort, several genetic variants in the UGT1A gene are common, but prevalence in a population may differ because of ethnicity. A phenotype based on bilirubin levels has limitations in serving as an indicator of pharmacogenetic differences in glucuronidation due to the influence of gender. Because of possible substrate overlap regarding different UGT1A isoforms, determination of haplotypes of potential cis-acting polymorphisms in the UGT1A gene should be considered in pharmacogenetic association studies regarding drugs that undergo glucuronidation.
OBJECTIVES: The objective of this study was to investigate the prevalence of different polymorphisms and haplotypes associated with individual variations in pharmacokinetics and drug toxicity in the uridine-diphosphate glucuronosyl transferase (UGT) 1A gene in a Swedish cohort (248 healthy volunteers) and in 14 different ethnic groups. We also estimated UGT1A genotype-dependent glucuronidation efficiency using the endogenous substrate bilirubin as an indicator. METHODS: Pyrosequencing-based genotyping assays were used to determine the different polymorphisms and haplotypes. RESULTS: Haplotype analysis of the UGT1A1 (*1*28), UGT1A6 (*1*2), and UGT1A7(*1*2*3*4) allelic variants showed that three major haplotypes constituted 84% of the allelic variants in the cohort. We identified 15 haplotypes altogether from all groups, including previously undescribed haplotypes. Testing for the association of genotype and total bilirubin levels (nonfasting) in plasma disclosed that homozygous carriers of the TA allele, irrespective of haplotype combinations, had increased levels of bilirubin compared with noncarriers, but a gender-associated difference was observed. CONCLUSIONS: In a Swedish cohort, several genetic variants in the UGT1A gene are common, but prevalence in a population may differ because of ethnicity. A phenotype based on bilirubin levels has limitations in serving as an indicator of pharmacogenetic differences in glucuronidation due to the influence of gender. Because of possible substrate overlap regarding different UGT1A isoforms, determination of haplotypes of potential cis-acting polymorphisms in the UGT1A gene should be considered in pharmacogenetic association studies regarding drugs that undergo glucuronidation.
Authors: Christian Meisel; Thomas Gerloff; Julia Kirchheiner; Przemyslaw M Mrozikiewicz; Przemyslaw Niewinski; Jürgen Brockmöller; Ivar Roots Journal: J Mol Med (Berl) Date: 2003-03-15 Impact factor: 4.599
Authors: Leonie C Jacobs; Andreas Wollstein; Oscar Lao; Albert Hofman; Caroline C Klaver; André G Uitterlinden; Tamar Nijsten; Manfred Kayser; Fan Liu Journal: Hum Genet Date: 2012-10-11 Impact factor: 4.132
Authors: Fan Liu; Andreas Wollstein; Pirro G Hysi; Georgina A Ankra-Badu; Timothy D Spector; Daniel Park; Gu Zhu; Mats Larsson; David L Duffy; Grant W Montgomery; David A Mackey; Susan Walsh; Oscar Lao; Albert Hofman; Fernando Rivadeneira; Johannes R Vingerling; André G Uitterlinden; Nicholas G Martin; Christopher J Hammond; Manfred Kayser Journal: PLoS Genet Date: 2010-05-06 Impact factor: 5.917
Authors: Christoph Schulz; Volker Heinemann; Andreas Schalhorn; Nikolas Moosmann; Thomas Zwingers; Stefan Boeck; Clemens Giessen; Hans-Joachim Stemmler Journal: World J Gastroenterol Date: 2009-10-28 Impact factor: 5.742
Authors: B Glimelius; H Garmo; A Berglund; L A Fredriksson; M Berglund; H Kohnke; P Byström; H Sørbye; M Wadelius Journal: Pharmacogenomics J Date: 2010-02-23 Impact factor: 3.550
Authors: Hui Huangfu; Hong Pan; Binquan Wang; Shuxin Wen; Rui Han; Li Li Journal: Int J Environ Res Public Health Date: 2016-01-07 Impact factor: 3.390